Psyomics, a UK-based mental health diagnosis spinout from University of Cambridge, has raised an undisclosed sum of funding from University of Cambridge Enterprise Fund V and Parkwalk Opportunities Fund.
University of Cambridge Enterprise Fund invests in Cambridge technologies behalf of university alumni and the private sector, while Parkwalk Opportunities Fund backs UK-based technology businesses under a government tax break scheme.
Both vehicles are operated by commercialisation firm Parkwalk Advisors.
PsyOmics is developing a mental health diagnosis tool that uses biomarker indicators from the blood along with data from wearable monitors and questionnaires. It hopes the approach will remove some of the uncertainties surrounding conventional mental health diagnosis.
The spinout is based on research at University of Cambridge’s Department of Chemical Engineering and Biotechnology.
Parkwalk Advisors invested an undisclosed sum in July 2016 for which deals database PitchBook put the figure at $530,000, though it is unclear which Parkwalk vehicle took part. PitchBook also recorded a $90,000 seed round from undisclosed backers in March 2016.
